tbuckley/cabot-search huggingface dataset:
Analysis of c-erb-1 (EGFR) and c-erb-2 (HER2) expression in bronchial dysplasia: Evaluation of potential targets for chemoprevention of lung cancer
Authors: D. T. Merrick, J. Kittelson, R. Winterhalder, G. Kotantoulas, S. Ingeberg, R. L. Keith, T. C. Kennedy, Y. E. Miller, W. A. Franklin, F. R. Hirsch
Journal: Journal of Clinical Oncology (2006)

7070 Background: Lung cancer is preceded by a premalignant phase during which intervention could decrease associated morbidity and mortality. Molecular characterization of factors involved in controlling progression of bronchial dysplasia (BD) will provide markers of premalignant change and identify targets for chemoprevention. Methods: Immunohistochemical (IHC) analysis of EGFR, HER2, Ki67 and MCM2 expression in BD was undertaken in 268 bronchoscopically obtained biopsies from 134 consecutive subjects recruited to University of Colorado protocols as study subjects with prior sputum atypia and &gt;20 pack years tobacco use or FEV1 &lt; 75% predicted or as never- or healthy-smoker controls. IHC on the worst and best histologic biopsies from each subject were scored and linear regression tests were used to determine significance of correlation between marker expression and histology or proliferation. Results: Analysis of biopsies with the most severe diagnosis from each subject showed a linear relationship between increasing marker expression and severity of dysplastic change for EGFR (p &lt; 0.001), Ki67 (p &lt; 0.001) and MCM2 (p = 0.001) but not HER2 (p = 0.102). Increased expression of either EGFR or HER2 was associated with increased expression of proliferation markers Ki67and MCM2, and combined overexpression of these receptors was associated with the highest levels of proliferation. Finally, in a comparison of subjects that were grouped according to the degree of difference between their best and worst biopsy histology, the absence of an associated trend toward increased EGFR expression with increased difference in histology suggested a field effect in the induction of EGFR expression. Conclusions: Our results 1) demonstrate a direct correlation between levels of EGFR expression and degree of BD, 2) suggest a field effect in the induction of EGFR expression in the airways of subjects with BD and 3) indicate a potential synergistic effect on epithelial proliferation in lesions with increased expression of both EGFR and HER2. These findings suggest that EGFR plays a prominent role in the development and progression of BD and could provide a promising target for chemoprevention of lung cancer. [Table: see text]
Abstract 16857: Design and Implementation of a Prehospital Electrocardiogram Remote Transmission and Data Recording App for Acute Myocardial Infarction Based on WeChat in China
Authors: Yuxi Li, Yan Zhang, Hongmei Liu, Dou Li, Jianping Li, Yong Huo
Journal: Circulation (2015)

Introduction: There were evidences showing prehospital electrocardiogram (ECG) remote transmission could reduce door-to-balloon (D2B) time in ST-segment elevation myocardial infarction (STEMI) care. There is spacious room for improvement due to low ratio of tele-ECG transmission usage in China. Meanwhile, the collection of prehospital clinical data, especially key time points during emergency care is not sufficient. The existing systems for ECG transmission require unique hardware leading to poor cost-benefits. We designed a mobile app to solve these problems based on WeChat, the most popular messaging communication app in China, which can transmit clear images of high quality and has a monthly-active-user of 549 million. Hypothesis: We assessed the hypothesis that such an app could solve the problems above in China. Methods: Firstly, we included 192 PCI hospitals together with their global positioning system (GPS) coordinates and telephone numbers into the database throughout China. Once an ECG image is sent through the app, ECG image, transmission time and sender’s GPS coordinates will be automatically recorded onto the server; the app will reply with a multimedia message listing nearby PCI hospitals, which can be contacted by clicking the specific link easily. At the same time, the on-call physician in the PCI hospital will receive a short message containing the ECG. Furthermore, an automatically generated electronic form evaluating prehospital treatment delay is also provided, in which the key time points can be recorded by clicking. Results: We performed a field test for a STEMI case, it took 20 seconds sending ECG and feedback message was received in 2 seconds, the responding physician in the PCI hospital stated ECG image was clear enough to interpret and all key time points were traceable. A pilot study is being conducted in a regional network including 4 PCI hospitals and 13 non-PCI hospitals in Tianjin. Conclusions: In conclusion, this is a low cost novel digital system integrated with daily communication service app on prehospital emergency care for STEMI to solve the problems of prehospital ECG remote transmission and prehospital clinical data recording in China. The effect on D2B time and outcomes requires further study.
Tissue Is the Issue: Accuracy of PET Imaging to Detect Bone Marrow Clearance in Patients with Peripheral T-Cell Lymphoma
Authors: Anthony Q Pham, Stephen Broski, Thomas M. Habermann, Dragan Jevremovic, Gregory Wiseman, Andrew L Feldman, Matthew J Maurer, Kay Ristow, Thomas E. Witzig
Journal: Blood (2015)
Consolidation reduced dose whole brain radiotherapy (rdWBRT) following methotrexate, rituximab, procarbazine, vincristine, cytarabine (R-MPV-A) for newly diagnosed primary CNS lymphoma (PCNSL): Final results and long-term outcome.
Authors: Richard Charles Curry, Denise Correa, Jeffrey J. Raizer, Sean Aaron Grimm, Rose Lai, David Schiff, Barbara W. Grant, Anne S. Reiner, Katherine Panageas, Joachim Yahalom, Lisa Marie DeAngelis, Lauren E. Abrey, Patrick Glyn Morris, Antonio Marcilio Padula Omuro
Journal: Journal of Clinical Oncology (2012)

2006 Background: After promising early results in the pilot phase (N= 30) reported by Shah 2007, we report on final results of a multicenter phase II study (N=52) in newly diagnosed PCNSL combining R-MPV-A and rdWBRT, expanded to address long-term disease control and cognitive outcomes in pts who actually received rdWBRT. Methods: Pts received 5 cycles of R-MPV (MTX dose: 3.5g/m2). Those with partial response (PR) received additional 2 cycles. Pts with a complete response (CR) after 5-7 cycles received rdWBRT (23.4 Gy), otherwise standard WBRT was offered (45 Gy). Consolidation cytarabine was given to all pts. Primary end-point was 2-y progression-free survival (PFS) in pts receiving rdWBRT (n=30 pts in CR required). Exploratory end-points included comprehensive neuropsychological testing, white matter changes (WMC) analysis (Fazekas scale) and apparent diffusion coefficient (ADC) on MRI. Results: Accrual was completed (N=52; 22 women); median (med) age= 60 (30-79); med KPS= 70 (50-100). In total, 31 (59%) pts were assessable for the primary endpoint (achieved a CR after induction and received rdWBRT). The 2-y PFS for this group was 78% (95% ci: 64%- 92%); med PFS= 7.7 y; the med OS was not reached (med follow-up= 6y); 3y-OS= 88% (ci 70-95); 5y-OS= 81% (ci 62-91). Cognitive testing showed improvement in executive function (P &lt; 0.01) and verbal memory (P &lt; 0.05) following induction chemotherapy; follow-up scores remained stable across the various domains. Minimal WMC developed in long term survivors: 36% of pts showed no change in Fazekas’ scores, 64% of pts developed scores 1 or 2 and no pt showed scores 3-6. The intent-to-treat (n=52) med PFS was 3.3y; med OS= 6.6 y. Differences in ADC values did not predict response (p=0.15), PFS (p=0.41) or OS (p=0.48). Conclusions: Consolidation rdWBRT is a highly effective and safe treatment for newly diagnosed PCNSL. Long term follow-up showed robust PFS and OS, comparable or superior to full dose WBRT, with excellent cognitive outcomes and no significant WMC over time. An RTOG randomized trial has been initiated comparing R-MPV-A with vs without rdWBRT.
Antithymocyte Globulin Improves the Survival of Patients with Myelodysplastic Syndrome Undergoing HLA-Matched Unrelated Donor and Haplo-Identical Donor Transplants
Authors: Miao Miao, Hong Wang, Hong Liu, Jinyi Zhou, Tongtong Zhang, Song Jin, Xiang Zhang, Suning Chen, Weiyang Li, Yang Xu, Depei Wu
Journal: Blood (2016)
Evaluation of Endothelial Damage in Sinusoidal Obstructive Syndrome
Authors: Nora Butta, Carmen de Ramón, Raul Justo Sanz, Elena Monzon Manzano, Ihosvany Fernandez Bello, Mercedes Gasior, Raquel De Paz, Karem Humala, Pilar Gomez, Ana Lopez de la Guia, Marta Fabra, Miguel Canales, Victor Jiménez Yuste
Journal: Blood (2016)
TRANSAPICAL TAVR IS ASSOCIATED WITH HIGHER MORBIDITY AND MORTALITY COMPARED TO TRANSFEMORAL TAVR IN MEN BUT NOT IN WOMEN
Authors: Salman Atiq Arain, Yelin Zhao, Jaafer Al-Khafaji, Kaleb Lambeth, Abhijeet Dhoble, Tom Nguyen, Pranav Loyalka, Biswajit Kar, Richard Smalling, Prakash Balan
Journal: Journal of the American College of Cardiology (2017)
Vertebral Hemangioma Mimicking Bone Metastasis in 68Ga—PSMA Ligand PET/CT
Authors: Carlos Artigas, François-Xavier Otte, Marc Lemort, Roland van Velthoven, Patrick Flamen
Journal: Clinical Nuclear Medicine (2017)

Ga-PSMA PET/CT was performed in a 68-year-old man to evaluate recurrent prostate cancer due to elevated serum prostate-specific antigen level. Images showed a focal uptake in the prostatic gland, suggesting local relapse, and an intense uptake in the 12th thoracic vertebra, with no morphological abnormalities in CT slices. In order to confirm extraprostatic disease and before radiotherapy planning, a full-spine MRI was performed, resulting with the morphological pattern of a vertebral hemangioma. Hystological analysis confirmed the local relapse in the prostate. No radiotherapy treatment was given to the vertebra, and after 1 year of follow-up without systemic treatment, prostate-specific antigen is still undetectable.
Quality of life and safety profile of pemetrexed-platinum doublet in Indian adult chemo-naive NSCLC patients.
Authors: Vikram Gota, Krunal Vasant Kavathiya, Damodaran S E, Amit Joshi, Vanita Noronha, Kumar Prabhash
Journal: Journal of Clinical Oncology (2013)

e19118 Background: Pemetrexed in combination with cisplatin or carboplatin is commonly recommended for the first-line treatment of patients with locally advanced or metastatic NSCLC of adenocarcinoma histology. The present study explores the safety and the impact of this doublet on the quality of life in adult Indian NSCLC patients. Methods: Patients were enrolled from a single tertiary care cancer hospital in India. Patients were administered pemetrexed 500 mg/m 2 , cisplatin 75 mg/m 2 or carboplatin AUC 5 every 3 weekly. All patients received standard folate and Vitamin B12 supplementation. Premedication included dexamethasone, granisetron and ranitidine. Quality of Life (QoL) data was collected at baseline and at completion of 3 cycles using EORTC QLQ-C30 (version 3) and QLQ- LC13 questionnaires. Toxicity was graded using CTCAE v. 4.03. Results: Twenty seven patients were enrolled on the study since July 2012.Twenty received carboplatin and seven received cisplatin. Mean age of the participants was 54.7 years (SD=9.58) with stage (IV=25; III A/B=2) and ECOG performance status (0=1; 1=17; and 2=9). Pemetrexed–platinum doublet caused significant improvement in Global Health Status and dyspnea score at 3 cycles compared to baseline (Table). The treatment also caused marked improvement in the physical function, emotional function, cognitive function and insomnia scales, although not statistically significant (Table). No significant difference compared to baseline was observed for other parameters. Grade 3/4 toxicities include anemia (3), neutropenia (3), hyponatremia (6), vomiting), diarrhea, and dyspnea (1 each). Conclusions: Pemetrexed-platinum doublet was well tolerated and markedly improved the global health status and dyspnoea at the end of three cycles. A higher incidence of hyponatreemia was observed in our cohort that needs to be investigated further. [Table: see text]
Significance of the vimentin expression in triple-negative breast cancer.
Authors: Nami Yamashita, Eriko Tokunaga, Hiroyuki Kitao, Kimihiro Tanaka, Kenji Taketani, Hiroshi Saeki, Shinichi Aishima, Eiji Oki, Masaru Morita, Yoshihiko Maehara
Journal: Journal of Clinical Oncology (2013)

1056 Background: Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). The treatment of patients with TNBC has been challenging due to the absence of these molecular targets and the heterogeneity of the disease. Therefore a better understanding of the molecular and histopathological features of TNBC and its heterogeniety is important for the development of a new therapeutic strategy and to improve the prognosis of TNBC. Recent studies suggest that there are links between TNBC and the epithelial-mesenchymal transition (EMT). To identify prognostic biomarkers and novel therapeutic targets, vimentin one of the most major factors associated with EMT was investigated in TNBC. Methods: Sporadic invasive ductal carcinoma specimens were obtained from 659 Japanese patients, and 90 (14%) cases were diagnosed as TNBC. The vimentin mRNA and protein expression levels were evaluated by quantitative RT-PCR and immunohistochemistry. Results: The mRNA expression of vimentin was significantly upregulated in the basal type breast cancer cell line. Immunohistochemically, the vimentin expression was significantly higher (p=0.0042) in TNBC compared to the other subtypes. Vimentin expression was associated with a younger age (p=0.016), high nuclear grade (p=0.023) and high Ki67 expression (p&lt;0.0001), and a poorer prognosis in terms of both the recurrence-free survival (RFS) (p=0.0058) and overall survival (OS) (p=0.013) in TNBC patients. A multivariate analysis showed that vimentin expression was an independent prognostic factor for the RFS (p=0.043). Vimentin expression was also associated with a significantly shorter RFS (p=0.021) and OS (p=0.017) in patients with basal-like breast cancer (BLBC). Conclusions: The elevated expression of vimentin contributes to the aggressive phenotype and poor prognosis in TNBC. Vimentin expression might be useful as a biomarker for the prognosis of TNBC.
Decreasing early mortality (30-day) in APL patients with use of streamlined treatment guidelines and support from core group of experts.
Authors: Anand P. Jillella, Farrukh Tauseef Awan, Jeremy Mark Pantin, Ravindra B. Kolhe, Vamsi Kota
Journal: Journal of Clinical Oncology (2013)

7091 Background: Recent evidence from population based studies in Brazil and US SEER data show that the early mortality (EM) in APL is around 30%. This is in contrast to observation in clinical trials where it is 5%. The common causes of death are hemorrhagic complications (HC), infection, differentiation syndrome (DS) and multi-organ failure. HC are unique to this condition due to DIC and HC are seen in upto 60% of patients. Hence, decreasing early deaths is a high priority at all leukemia treatment centers. We report our updated results showing that use of set of streamlined treatment guidelines along with support from experts decreases early deaths. Methods: At Georgia Regents University, between 7/2005 and 6/2009, 19 patients were diagnosed with APL. 7 patients (5 high-risk and 2 low-risk) died during induction resulting in an unusually high mortality rate of 37%. All patients who survived induction are still in remission at present. The high early death rate prompted us to develop a simple, 2 page treatment algorithm that focuses on quick diagnosis, prompt initiation of therapy, and proactive and aggressive management of all the major causes of death during induction. We also made our treatment protocol available to smaller treatment centers and helped the treating oncologists manage the patient during the first few days after diagnosis. Results: From 11/2010 to 12/2012, we treated 5 patients at GRU and helped manage 9 patients at 5 practices. Age range was 30-60 years. 4 patients were high-risk, 7 intermediate and three low-risk. There were no deaths during induction. Only 1 patient (8%) had HC and 4 had DS. Conclusions: While we recognize that this is a small cohort, our own experience and a similar approach pioneered by investigators in Brazil clearly shows this to be an effective model to decrease early deaths in APL. We believe our experience warrants large scale implementation of our protocol in an attempt to decrease early mortality in APL. We were awarded a 1.68 million grant by the Leukemia Lymphoma Society to implement this protocol in the states of Georgia and South Carolina with a catchment population of 15 million over a 3 year period.
Pulmonary Hypertension During Autologous Transfusion of Stored Blood Is Prevented by Nitric Oxide Inhalation in Lambs
Authors: David M. Baron, Binglan Yu, Chong Lei, Aranya Bagchi, Arkadi Beloiartsev, Andrea U. Steinbicker, Christopher P. Stowell, Rajeev Malhotra, Kenneth D. Bloch, Warren M. Zapol
Journal: Blood (2011)
A “tail” of opioid receptor variants
Authors: Stephanie Puig, Howard B. Gutstein
Journal: Journal of Clinical Investigation (2017)

Opioids are the gold-standard treatment for severe pain. However, potentially life-threatening side effects decrease the safety and effectiveness of these compounds. The addiction liability of these drugs has led to the current epidemic of opioid abuse in the US. Extensive research efforts have focused on trying to dissociate the analgesic properties of opioids from their undesirable side effects. Splice variants of the mu opioid receptor (MOR), which mediates opioid actions, have unique pharmacological properties and anatomic distributions that make them attractive candidates for therapeutic pain relief. In this issue of the JCI, Xu et al. show that specific C-terminal regions of the MOR can modulate side effects without altering analgesia. This discovery greatly improves our understanding of opioid side effects and suggests intriguing therapeutic approaches that could improve both the safety and long-term effectiveness of opioids.
EVALUATION OF RIGHT VENTRICULAR STRAIN BY ECHOCARDIOGRAPHY, COMPUTED TOMOGRAPHY, AND ELECTROCARDIOGRAPHY IN PATIENTS WITH ACUTE PULMONARY EMBOLISM
Authors: Brett Carroll, Dominique DaBreo, Jason Matos, Benedikt Heidinger, Donya Mohebali, Stephanie Feldman, Ian McCormick, Diana Litmanovich, Warren Manning
Journal: Journal of the American College of Cardiology (2017)
Timing between Rituximab and 90Y-Ibritumomab Tiuxetan in Pts with Non-Hodgkin’s Lymphoma Does Not Affect Clinical Outcomes.
Authors: Isaiah E. Friedman, Charalambos Andreadis, Yumi Taylor Diangi, Sunita D. Nasta, Selina M. Luger, Edward A. Stadtmauer, Stephen J. Schuster
Journal: Blood (2006)
DIFFERENCES IN CHRONIC ANGIOSCOPIC FINDINGS WITH DIFFERENT STENT TYPES IN PATIENTS WITH AND WITHOUT DIABETES MELLITUS: SUB-ANALYSIS OF A REPORT FROM JAPANESE MULTICENTER REGISTRY
Authors: Tetsuya Sato, Kazuoki Dai, Yasuharu Nakama, Kouki Watanabe, Hideo Kawakami, Hiroshi Matsuoka, Masaharu Ishihara
Journal: Journal of the American College of Cardiology (2017)
The 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2016). Advancing HCC Management through Multi-Disciplinary Approach. Hong Kong, SAR (China), July 8-10, 2016: Abstracts
Journal: Liver Cancer (2016)

Recent Advancement in HCC Treatment I. Heterogeneity of Intermediate Stage HCCThere is big heterogeneity in the intermediate stage HCC.Usually, TACE is performed in patients with multiple tumors, no vascular invasion and no extrahepatic spread.However, in Japan the nodules are fewer and smaller compared to Western countries and the other Asian countries, where tumors are larger or multilober nodules.Therefore, intermediate stage HCCs should be subclassified in order to select the optimal treatment option. II. New Trends of TACE ProcedureUntil now, the standard technique of TACE in Japan was superselective TACE using Lipiodol and gelatin sponge because of the fewer and smaller nodules in the liver.However, microsphere such as DC Beads or hepasphere was approved to use.In addition, balloon occluded TACE (B-TACE) was developed to achieve dense accumulation of anticancer agent.Optimal indication for each technique, i.e., conventional Lip TACE, DEB TACE or B-TACE should be should be determined in the near future. III. Definition of TACE FailureDefinition of TACE failure proposed by Japan Society of Hepatology is as follows: Definition of TACE Failure/Refractoriness (JSH) (1) Intrahepatic lesion i Two or more consecutive insufficient responses of the treated tumor (viable lesion >50%) even after changing the chemotherapeutic agents and/or reanalysis of the feeding artery seen on response evaluation CT/MRI at 1-3 months after having adequately performed selective TACE.ii Two or more consecutive progressions in the liver (tumor number increases as compared to tumor number before the previous TACE procedure) even after having changed the chemotherapeutic agents and/or reanalysis of the feeding artery seen on response evaluation CT/MRI at 1-3 months after having adequately performed selective TACE.(2) Continuous elevation of tumor markers immediately after TACE even though slight transient decrease is observed(3) Appearance of vascular invasion (4) Appearance of extrahepatic spread Two validation studies were conducted and proved that this definition is adequate.IV. Molecular Targeted Therapy: Current Status and Future Perspective Sorafenib is the only targeted agent that was proved to prolong the survival of the patients with advanced HCCs.During 7 years since its approval, 13 global studies that tested 1st line, 2nd line, TACE combination, and adjuvant setting after curative treatment failed.SILIUS trail that tested the survival benefit of hepatic arterial infusion chemotherapy plus sorafenib also failed.However, regorafenib after sorfenib failure as a second line treatment was proved to be an effective agent, that prolongs survival in patients with advanced HCC.Regorafenib will change the treatment paradigm in HCCs.